How it works

Ravulizumab is a type of drug called a monoclonal antibody. This means it is synthetic (made in a lab) and designed to bind to a specific target in the body. In the case of Ravulizumab, it binds to a component of our immune system, a protein called C5. C5 and other proteins like it initiate our immune response. By binding to C5, Ravulizumab suppresses the immune response that causes symptoms of myasthenia.

How it is delivered

Ravulizumab is delivered via intravenous infusion (IV), meaning it comes through a drip into the vein.

When you have it

The IV treatment is carried out at a hospital under supervision by a healthcare professional. You will have an initial loading infusion, then 2 weeks later a maintenance infusion every 8 weeks (the length of time between infusions can be affected by weight).

Side Effects

When starting a new medication, you may experience unwanted side effects. You may find these side effects lessen or disappear as your body adjusts to treatment. Side effects associated with Ravulizumab are:

• Back pain
• Diarrhoea
• Dizziness

Your doctor will go through an extended list of possible side effects and monitor your response to Ravulizumab. If you have any questions or concerns, please check in with your doctor to alleviate them. Ravulizumab is a new medication currently available through EAMS. While there may not be many other people being treated with this medication, you may find that other members of myaware have received it and may be willing to share their experiences.

Manufacturer:

Alexion (rare disease group of AstraZeneca)

FAQs

You are advised to be on effective contraception while being treated with Ravulizumab. It is a new medicine and therefore the effect it may have on pregnancy has not yet been explored. If you become pregnant while being treated, consult your doctor as soon as possible.

The manufacturer advises you do not breastfeed during and up to 8 months after treatment.

Report any side effect you have to the Medicines Health and Regulatory Authority (MHRA) as part of their Yellow Card Scheme.

Click here to report a side effect to the MHRA.

Treatments